EyePoint announces DSMC completed review of Phase 3 trial for DURAVYU

EyePoint (EYPT) Pharmaceuticals announced that the independent Data Safety Monitoring Committee, DSMC, completed its second scheduled review of the Company’s ongoing pivotal Phase 3 program evaluating DURAVYU for the treatment of wet age-related macular degeneration, wet AMD. As of the September 29, 2025 data cutoff for the DSMC review, all patients across the LUGANO and LUCIA trials reached the Week 8 visit during which patients in the DURAVYU arms received their initial DURAVYU dose, and approximately 25% of those patients received their second planned dose of DURAVYU at Week 32. The DSMC recommended that both the LUGANO and LUCIA trials continue as planned, with no modifications to the protocol. The DSMC is an independent panel of experts in ophthalmology and biostatistics who are responsible for reviewing safety data to ensure the welfare of trial participants and to provide recommendations regarding trial conduct. DSMC meetings are scheduled to occur every six months per the trial protocol.